Business Context and Reporting Period
Jasper Therapeutics, Inc. filed a Form 8-K regarding board leadership changes and a related director appointment. The report date and earliest event date were October 30, 2023; the appointment became effective November 1, 2023. The company is a biotechnology issuer headquartered in Redwood City, California, with common stock trading as JSPR and warrants trading as JSPRW on Nasdaq.
Key Financial Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics. It is not a financial-results filing.
Material Changes
- Thomas G. Wiggans was appointed as a Class II director effective November 1, 2023, and became Chairperson of the Board.
- William Lis stepped down as Chairperson effective upon Mr. Wiggans’s appointment and notified the Board of his intent to resign as a director effective December 14, 2023.
- Mr. Lis’s resignation was not related to any disagreement with the company’s operations, policies, or practices.
- Mr. Wiggans received an option to purchase 110,000 shares of common stock. The exercise price equals the closing market price on the grant date. Twenty-five percent vests on the one-year anniversary, with the remainder vesting monthly over the following 36 months, subject to continued service.
- The option grant exceeds the standard 94,000-share new-director grant because Mr. Wiggans is also serving as Board Chair.
- Mr. Wiggans is entitled to standard cash retainers for Board Chair and committee service and entered into the company’s standard director indemnification agreement.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or business outlook. Mr. Wiggans brings prior executive and board experience at biotechnology and pharmaceutical companies, including Dermira, Pardes Biosciences, Annexon, and CymaBay Therapeutics.
The filing states that Mr. Wiggans has no family relationship with any director or executive officer, was not appointed pursuant to an arrangement or understanding with another person, and has no reportable related-party transaction under Item 404(a) of Regulation S-K.
Facts Investors Should Verify
- Completion of Mr. Lis’s planned resignation effective December 14, 2023.
- Final terms, grant-date exercise price, and accounting treatment of the 110,000-share option.
- Any subsequent changes to Board composition, committee assignments, or director compensation.
- Financial condition, cash runway, operating performance, and clinical or regulatory developments in the company’s subsequent periodic filings, which are not addressed in this 8-K.